FY2026 EPS Estimates for Replimune Group Lowered by Analyst

Replimune Group, Inc. (NASDAQ:REPL) – Equities researchers at Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for Replimune Group in a research note issued on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($3.73) per share for the year, down from their prior estimate of ($3.08). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($2.97) per share.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03).

A number of other equities analysts have also issued reports on the stock. Barclays lowered shares of Replimune Group from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Monday, October 20th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $3.00 to $13.00 in a research note on Monday, October 20th. JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Replimune Group in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Replimune Group has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Replimune Group Stock Down 2.4%

Shares of NASDAQ:REPL opened at $8.77 on Monday. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $687.92 million, a P/E ratio of -2.53 and a beta of 0.79. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company’s 50-day moving average price is $6.50 and its two-hundred day moving average price is $7.39.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the stock. Readystate Asset Management LP increased its holdings in Replimune Group by 1,296.2% in the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares during the last quarter. Braidwell LP grew its position in shares of Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. increased its stake in shares of Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after acquiring an additional 2,195,448 shares during the last quarter. Erste Asset Management GmbH raised its position in shares of Replimune Group by 13,597.5% in the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after acquiring an additional 1,618,100 shares during the period. Finally, Nuveen LLC bought a new position in Replimune Group during the 1st quarter worth approximately $6,546,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.